Motivation
⋄ The "lack of objectivity" has been frequently argued as the main concern precluding the adoption of Bayesian techniques in pharmacoeconomy.
⋄ However this legitime concern has inspired a fruitful area of research in the statistical community: the development of formal objective Bayesian methods.
⋄ In this work, we
• analyze how these methods accommodate the needs of pharmacoeconomic studies,
• fully develop the methodology in two important cost effectiveness (CE) problems,
• study the differences with other approaches to PSA.
The problem
⋄ A great number of CE studies use complex decision models, which is a joint density for the outcomes cost and effectiveness, given a number of unknown calibration parameters (θ) like transition probabilities.
⋄ The complex decision models are used as a device to produce simulated observations of cost and effectiveness of hypothetical cohorts under study.
Examples of these models are the decision trees and the Markov models.
⋄ In a probabilistic sensitivity analysis of a CE study the key question is how to assign the probability density of θ (to be denoted p(θ)).
⋄ This density should reflect objectively relevant historical data about θ (eg. clinical trials).
3. Approaches to assign probability densities for calibration parameters ⋄ Two stage approach: adjust a triangular density (or similar) to confidence intervals obtained from the historical data.
⋄ Comprehensive decision modeling: assign p(θ) as the posterior distribution, with respect to some 'vague' or 'flat' prior.
FORMAL OBJECTIVE BAYESIAN:
Assign p(θ) as the posterior distribution with respect to a formal objective prior.
A formal objective prior is a distribution derived by using some formal rules. They do not contain any extra information and have a number of good properties.
Illustrative example I: Survival analysis
Kamath et al (2003) perform a CE analysis regarding several treatments of symptomatic knee osteoarthritis. They use a decision tree with effectiveness the number of upper gastrointestinal (UGI) adverse events averted. We focus on θ, the probability of developing an UGI event in the six months after starting the treatment with ibuprofen. The historical data used is the CLASS study, a survival analysis with 1985 patients enrolled.
---Objective Bayesian approach---
We derive an objective posterior distribution for θ, based on a Weibull model for the data in CLASS and the formal objective prior obtained by Sun (1997).
- Objective posterior distribution. Fitted triangular distribution.
• The triangular is slightly placed on the right and with much more variability.
• The mean of θ under the objective posterior distribution is 0.017, while under the triangular is 0.025 (more than 45% larger).
Illustrative example II: Meta analysis
Goeree et al (1999) perform a CE study concerning several strategies for the management of patients with gastro-oesophageal reflux disease (GORD). A key parameter is θ, the GORD healing probability at 12 weeks with cisapride. The historical data corresponds to 9 different trials with a total of 211 patients. Objective posterior distribution. Fitted (transformed) beta distribution.
• Both distributions are quite different in the tails, being those of the transformed beta shorter.
• The more variability of θ add new elements of discussion about the conclusions in the original study. 
